In clinical patients, SIRT2 is downregulated in the NALFD patients compared with healthy controls, and is associated with exacerbated progression of normal liver status to NAFLD to NASH in clinical patients. This evidence concerns the gene SIRT2 and metabolic dysfunction-associated steatohepatitis.